[(64)Cu]‐labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice

The human epidermal growth factor receptor‐2 (HER2) is overexpressed in 20–30% of all breast cancer cases, leading to increased cell proliferation, growth and migration. The monoclonal antibody, trastuzumab, binds to HER2 and is used for treatment of HER2‐positive breast cancer. Trastuzumab has prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Schjoeth‐Eskesen, Christina, Nielsen, Carsten Haagen, Heissel, Søren, Højrup, Peter, Hansen, Paul Robert, Gillings, Nic, Kjaer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029596/
https://www.ncbi.nlm.nih.gov/pubmed/25906708
http://dx.doi.org/10.1002/jlcr.3287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029596/
https://www.ncbi.nlm.nih.gov/pubmed/25906708
http://dx.doi.org/10.1002/jlcr.3287

Ejemplares similares